Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

l minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. A replay of the webcast will be archived on the Sunesis website for two weeks until March 25, 2008.

About Sunesis' Oncology Programs

Sunesis has built a portfolio of product candidates in oncology focused on inhibition of the cell-cycle and survival signaling. Our lead product candidate, SNS-595, is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. SNS-595 is a specific DNA intercalator and topoisomerase II poison, causing replication-dependent site-selective double-strand DNA damage, irreversible G2 arrest and rapid apoptosis. A Phase 2 single agent clinical trial of SNS-595 in ovarian cancer and a Phase 1b clinical trial of SNS-595 combination with cytarabine in relapsed/refractory AML are both ongoing. SNS-032, a potent and selective inhibitor of CDKs 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory CLL or multiple myeloma. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other protein kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information o
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 PathoGenetix, Inc., a commercial-stage ... typing, announced today that it has successfully identified and ... strains obtained from the Centers for Disease Control and ... technology. The findings are detailed in a poster ... Society for Microbiology in Denver on Monday. , The ...
(Date:5/21/2013)... May 21, 2013 Clinovo's new ... 8-week training program starting on June 11th, 2013. The ... trial professionals reach the next step in their professional ... in Palo Alto, and streamed online. , Taught by ... papers, Clinovo's new “CDISC Standards: Theory and Application” class ...
(Date:5/20/2013)... Grace Century , an international ... science and health related private equity projects, has announced ... Project Team. Dergham's expertise in finance and international law ... Grace Century as it continues to look at more ... holds both an under graduate degree from the University ...
(Date:5/20/2013)... May 20, 2013  MiMedx Group, Inc. (NASDAQ: ... of patent protected regenerative biomaterials and bioimplants processed from ... a revolving line of credit with Bank of America.  ... by the Company,s accounts receivable and inventory, allows MiMedx ... 2014.  The facility will be used for general corporate ...
Breaking Biology Technology:New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3Clinovo Launches TechTrainings on CDISC Standards 2Dalia Dergham Joins Grace Century FZ LLC International Project Team 2
... (Nasdaq and MTAX: CTIC) announced that in a special ... the,Company,s articles of incorporation to increase the number of ... increase the number of,authorized shares of common stock from ... Chief Financial Officer at CTI, who chaired the,meeting, said ...
... HILLS, Mass., Jan. 28 Joseph F. Finn, Jr.,CPA, ... today,announced the completion the sale of the Company,s fixed ... January 24th. In addition, due to,the high volume of ... purchase of the intellectual property, the Company has,created an ...
... KNDL ), a,leading, global full-service clinical research organization, ... Kendle, PharmD,will participate in the Wachovia 2008 Healthcare ... Hotel in Boston, Jan. 29-31, 2008. Kendle,s,presentation is ... Eastern Time., (Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO ), ...
Cached Biology Technology:Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders 2Kendle to Present at the Wachovia 2008 Healthcare Conference 2
(Date:5/20/2013)... is known about the effect of physical education (PE) ... University finds that increasing the amount of time that ... of obesity. , The study represents some of the ... youth obesity, and is forthcoming in the Journal ... of the study can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 ...
(Date:5/20/2013)... conducted at the University of Bristol and published online ... sheds light on how the brain and inner ear ... School of Earth Sciences, together with Tom Hbner from ... of 150 million year old dinosaurs. , The two ... Dysalotosaurus lettowvorbecki : a very young (juvenile) individual ...
(Date:5/18/2013)... 2013) The AGA Research Foundation is honored to ... Award in Digestive Cancer, which will support Andrew D. ... the University of Pennsylvania, Philadelphia, as he furthers his ... regeneration and cancer progression. , "The AGA Research Foundation ... two distinguished clinicians and AGA Legacy Society members," said ...
Breaking Biology News(10 mins):Gym class reduces probability of obesity, study finds for first time 2Fossil brain teaser 2AGA Research Foundation grant furthers digestive cancer research 2
... PatientSecure(TM) on Display at Leading Healthcare Conference, ... 20 Identity,management in a busy healthcare ... especially when it must be repeated with ... Inc., a leading supplier of,innovative computer products, ...
... team of researchers led by the Smithsonian Institution has ... to as the hobbit, a 3-foot-tall, 18,000-year-old hominin skeleton, ... Flores. This study offers one of the most striking ... an island remnant of one of the oldest human ...
... Women with low levels of vitamin D have an ... by the University of Pittsburgh Graduate School of Public Health ... American Society for Bone and Mineral Research at the Hawaii ... and colleagues evaluated patient data on 400 women enrolled in ...
Cached Biology News:Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 2Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 3Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 4New research sheds light on 'Hobbit' 2Low vitamin D linked to higher risk of hip fracture 2
... We deliversoluble protein or No Charge ... the best soluble protein results , 24 ... submitted , Powerful results on your most ... Optimization Service (SOS) uses proprietary tools and ...
... for proteomic scale kinase profiling, quantitative ... drug discovery research built on the ... synthesis platform. These microarrays are available ... Kinase Substrate - Peptide Microarray Service. ...
... immunological studies, vaccine development, and biosensor ... powerful Paraflo microfluidic on-chip synthesis platform. ... of our comprehensive Epitope Peptide Microarray ... Probe content is completely customer ...
... Introducing our Regulatory Edition of Molecular ... imaging systems for life science research and ... supports compliance with U.S. Food and Drug ... Part 11 Electronic Records; Electronic Signatures [21 ...
Biology Products: